Skip to main content

Table 1 Demographic and clinical characteristics before and after propensity score matching

From: Long-term outcomes of robot-assisted versus minimally invasive esophagectomy in patients with thoracic esophageal cancer: a propensity score-matched study

Characteristics

Before matching

 

After matching

 
 

MIE

RAMIE

P value

MIE

RAMIE

P value

No. of patients (%)

43

43

 

26

26

 

Median age: years (range)

 68(50–78)

65(47–78)

0.472

67.5(50–76)

66(47–77)

0.832

<65 / 65–75 / >75

16(37.2)/ 25(58.1)/2(4.7)

21(48.8)/19(44.2)/3(7.0)

 

9(34.6)/16(61.5)/1(3.8)

9(34.6)/15(57.7)/2(7.7)

 

Sex

  

0.750

  

0.574

 Male / Female

37(86.0)/6(14.0)

38(88.4)/5(11.6)

 

23(88.5)/3(11.5)

24(92.3)/2(7.7)

 

BMI

20.7(16–29)

21.7(18–28)

0.830

20.8(15.7–28.8)

23.0(18.1–28.3)

0.376

 <18.5 / 18.5 < BMI < 25 / >25

6(14.0)/32(74.4)/5(11.6)

5(11.6)/33(76.7)/5(11.6)

 

4(15.4)/19(73.1)/3(11.5)

3(11.5)/18(69.2)/5(19.2)

 

Smoking (Brinkman Index)

  

0.791

  

0.587

 None / <400 / >400

9(20.9)/2(4.7)/32(74.4)

8(18.6)/2(4.7)/33(76.7)

 

4(15.4)/0(0)/ 22(84.6)

5(19.2)/1(3.8)/20(76.9)

 

Alcohol

  

0.301

  

1.000

 None / Opportunity / Habitual

4(9.3)/9(20.9)/30(69.8)

3(7.0)/5(11.6)/35(81.4)

 

3(11.5)/3(11.5)/20(76.9)

3(11.5)/3(11.5)/20(76.9)

 

ASA

  

0.466

  

0.381

 1 / 2 / 3

13(30.2)/27(62.8)/3(7.0)

17(39.5)/23(53.5)/3(7.0)

 

11(42.3)/14(53.8)/1(3.8)

8(30.8)/16(61.5)/2(7.7)

 

Myocardial infarction

0(0)

1(2.3)

0.323

0(0)

0(0)

-

Heart failure

0(0)

1(2.3)

0.323

0(0)

0(0)

-

Cerebrovascular disease

2(4.7)

3(7.0)

0.650

1(3.8)

2(7.7)

0.574

Liver disease

1(2.3)

0(0)

0.323

0(0)

0(0)

-

Diabetes without chronic complications

4(9.3)

2(4.7)

0.403

2(7.7)

2(7.7)

1.000

Tumor Location

  

0.617

  

0.559

 Upper / Middle / Lower third

5(11.6)/16(37.2)/22(51.2)

2(4.7)/19(44.2)/22(51.2)

 

3(11.5)/11(42.3)/12(46.2)

2(7.7)/10(38.5)/14(53.8)

 

Histology

  

0.650

  

0.574

 SCC / Adeno

40(93.0)/3(7.0)

41(95.3)/2(4.7)

 

25(96.2)/1(3.8)

24(92.3)/2(7.7)

 

Clinical T factor

  

0.002

  

0.381

 1b / 2 / 3

19(44.2)/8(18.6)/16(37.2)

31(72.1)/8(18.6)/4(9.3)

 

15(57.7)/6(23.1)/5(19.2)

18(69.2)/4(15.4)/4(15.4)

 

Clinical N factor

  

0.085

  

0.032

 0 / 1 / 2

35(81.4)/8(18.6)/0(0)

29(67.4)/12(27.9)/2(4.7)

 

24(92.3)/2(7.7)/0(0)

18(69.2)/7(26.9)/1(3.8)

 

Clinical TNM stage

  

0.139

  

0.802

 I / II / III

18(41.9)/19(44.2)/6(14.0)

23(53.5)/18(41.9)/2(4.7)

 

15(57.7)/9(34.6)/2(7.7)

14(53.8)/10(38.5)/2(7.7)

 

Preoperative therapy

6(14.0)

2(4.7)

0.010

2(7.7)

2(7.7)

1.000

 None / NAC (FP) / NAC (FP) RT

21(48.8)/14(32.6)/8(18.6)

29(67.4)/11(25.6)/3(7.0)

 

18(69.2)/5(19.2)/3(11.5)

18(69.2)/5(19.2)/3(11.5)

 
  1. BMI: Body mass index, ASA: American Society of Anesthesiologists, SCC: Squamous cell carcinoma, Adeno: Adenocarcinoma, NAC: Neoadjuvant chemotherapy, FP: 5-FU + Cisplatin, NACRT: Neoadjuvant chemoradiotherapy